Murahashi, Y., Yano, F., Chijimatsu, R., Nakamoto, H., Maenohara, Y., Amakawa, M., . . . Saito, T. (2019). Oral administration of EP4-selective agonist KAG-308 suppresses mouse knee osteoarthritis development through reduction of chondrocyte hypertrophy and TNF secretion. Sci Rep.
Citação norma ChicagoMurahashi, Yasutaka, et al. "Oral Administration of EP4-selective Agonist KAG-308 Suppresses Mouse Knee Osteoarthritis Development Through Reduction of Chondrocyte Hypertrophy and TNF Secretion." Sci Rep 2019.
Citação norma MLAMurahashi, Yasutaka, et al. "Oral Administration of EP4-selective Agonist KAG-308 Suppresses Mouse Knee Osteoarthritis Development Through Reduction of Chondrocyte Hypertrophy and TNF Secretion." Sci Rep 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.